Le Lézard
Classified in: Covid-19 virus

2021 Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy - ResearchAndMarkets.com


The "Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy" report has been added to ResearchAndMarkets.com's offering.

The global market for chimeric antigen receptor (CAR) T-cell therapy is estimated to grow from $1.5 billion in 2021 to reach $7.6 billion by 2026, at a compound annual growth rate (CAGR) of 39.1% during 2021-2026.

Descriptive company profiles of the leading industry players, including AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Novartis AG, F. Hoffmann-La Roche and Takeda Pharmaceutical Co., Ltd.

CAR T-Cell Design and Evolution

Chimeric antigen receptors (CARs, also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR-T) are engineered receptors that graft an arbitrary specificity onto an immune effector cell (T cell). Typically, these receptors are used to graft the specificity of a monoclonal antibody onto a T-cell, with the transfer of their coding sequence facilitated by retroviral vectors. The receptors are called chimeric because they are composed of parts from different sources.

FDA Product Approvals

There are five chimeric antigen receptor (CAR) T-cell therapies currently approved by the U.S. FDA. In March 2021, Bristol Myers Squibb launched its FDA-approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma.

In February 2021, Bristol Myers Squibb launched Breyanzi (lisocabtagene maraleucel) after receiving FDA approval for its commercialization in the U.S. market. Breyanzi is a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma.

In July 2020, Kite Pharma, a subsidiary of Gilead Sciences, launched Tecartus after receiving FDA approval for its commercialization in the U.S. market. Tecartus (brexucabtagene autoleucel, formerly KTE-X19), is the first and only approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

On Aug. 30, 2017, Novartis announced that the U.S. FDA had approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

On Oct. 18, 2017, the U.S. FDA approved Yescarta (axicabtagene ciloleucel) (Kite Pharma Inc.), a cell-based gene therapy, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. It is a CD19-directed genetically modified autologous T-cell immunotherapy.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Introduction to Chimeric Antigen Receptor (CAR) T-Cell Therapy

Chapter 4 Impact of COVID-19 on the Market

Chapter 5 Market Dynamics

Chapter 6 Current Production Methods, Latest Technological Advances and Future Direction

Chapter 7 Clinical Trials on CAR T Cells and Related Technologies

Chapter 8 Cancer Demographics: A Global Summary

Chapter 9 Global CAR T-Cell Market Analysis

Chapter 10 Regional Analysis

Chapter 11 Regulatory and Legislative Requirements

Chapter 12 Patent Review/New Developments

Chapter 13 Global Competitive Market Landscape

Chapter 14 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/x1txa4


These press releases may also interest you

at 18:05
Athersys, Inc. , an international, late-stage, regenerative medicine company, announced today the appointment of Daniel A. Camardo as the Company's Chief Executive Officer, effective February 14, 2022. Mr. Camardo is a senior pharmaceutical and...

at 17:44
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired...

at 17:43
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired...

at 17:41
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons and entities that purchased or otherwise acquired...

at 17:38
Correctional Service Canada (CSC) advises that five inmates in the medium-security unit of Archambault Institution in Quebec have tested positive for COVID-19. The health and safety of our employees, inmates and the public continue to be our top...

at 17:36
Titan International, Inc. ("Titan" or "TWI") today released the following comments from its Chairman of the Board, Morry Taylor. "The USDA recently published data that that predicted a record number of acres will be planted in 2022.  I've spoken to...



News published on 17 december 2021 at 07:15 and distributed by: